Association of variations in the Fanconi anemia complementation group and prognosis in Non-small cell lung cancer patients with Platinum-based chemotherapy

Purpose: To explore the associations between FANG (FANCA, FANCC, FANCE, FANCF, and FANCJ) single nucleotide polymorphisms (SNPs) and prognosis of non-small cell lung cancer (NSCLC) patients with platinum-based chemotherapy. Methods: According to the inclusion criteria, we selected 395 DNA samples from NSCLC patients for genotyping and combined with clinical data for Cox regression analysis and stratification analyses to assess relationships between overall survival (OS) and progression free survival (PFS) with SNPs genotypes. Results: The results revealed that patients with FANCE rs6907678 TT genotype have a longer OS than TC and CC genotype (Additive model: P = 0.004, HR = 1.696, 95% CI = 1.186-2.425). In stratification analyses, Longer PFS is found in female, age <= 55 years old and non-smoking patients with FANCE rs6907678 TT genotype, and patients with TT genotypes were significantly had longer OS in male, age > 55 years old, non-smoking, squamous cell carcinoma and stage IV stratification. Conclusion: Our data demonstrates that patients with FANCE rs6907678 TT genotype are contributed to better prognosis. FANCE rs6907678 may be used as a clinical biomarker for predicting the prognosis of NSCLC patients with platinum-based chemotherapy.

Automated summary

This study explores the relationship between single nucleotide polymorphisms (SNPs) of FANG genes (FANCA, FANCC, FANCE, FANCF, and FANCJ) and the prognosis of non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy. The results suggest that patients with the TT genotype of the FANCE rs6907678 SNP have a better prognosis, and this SNP could potentially serve as a clinical biomarker for predicting the prognosis of NSCLC patients undergoing platinum-based chemotherapy.